|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Review of the current targeted therapies for non-small-cell lung cancer显示文摘The last decade has witnessed the development of oncogene-directed targeted therapies that have significantly changed the treatment of non-small-cell lung cancer(NSCLC). In this paper we review the data demonstrating efficacy of gefitinib, erlotinib, and afatinib, which target the epidermal growth factor receptor(EGFR), and crizotinib which targets anaplastic lymphoma kinase(ALK). We discuss the challenge of acquired resistance to these small-molecular tyrosine kinase inhibitors and review promising agents which may overcome resistance, including the EGFR T790 Mtargeted agents CO-1686 and AZD9291, and the ALKtargeted agents ceritinib(LDK378), AP26113, alectinib(CH/RO5424802), and others. Emerging therapies directed against other driver oncogenes in NSCLC including ROS1, HER2, and BRAF are covered as well. The identification of specific molecular targets in a significant fraction of NSCLC has led to the personalized deployment of many effective targeted therapies, with more to come. | Kim-Son H Nguyen Joel W Neal Heather Wakelee | 2014 | World Journal of Clinical Oncology2014，5，4： | 13 |
| 2 | Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab显示文摘 | H.A. Wakelee S.E. Dahlberg J.R. Brahmer J.H. Schiller M.C. Perry C.J. Langer A.B. Sandler C.P. Belani D.H. Johnson | 2011 | Lung Cancer2011，，3： | 3 |
| 3 | Optimizing first - line treatment op-tions for patients with advanced NSCLC 显示文摘 | Wakelee H Belani CP | 2005 | The Oncolo-gist2005，10，3： | 1 |
| 4 | Optimizing first - line treatment options for patient swith advanced no- small cell lung cancer(NSCLC) 显示文摘 | Wakelee H Belani CP | 2006 | Lung Cancer2006，51，3： | 1 |
| 5 | Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages Ⅱ and Ⅲ A non-small cell lung cancer( NSCLC ) does not increase the expected risk of death from intercurrent disease(DID) in eastern cooperative oncology group (ECOG) trial E3590显示文摘 | Wakelee H A Stephenson P Keller S M | 2005 | Lung Cancer2005，48，3： | 1 |
| 6 | Second-and third-line treatments in non-small cell lung cancer显示文摘 | Kumar A Wakelee H | 2006 | Curr Treat Options Oncol2006，7，1： | 1 |
| 7 | Targeting VEGF in lung cancer显示文摘 | DAS M WAKELEE H | 2012 | Expert Opin Ther Targets2012，16，4： | 1 |
| 8 | A phase I pharmaco-kinetic study of bexarotene with vinorelbine and cisplatin in patientswith advanced non-small-cell lung cancer ( NSCLC ) 显示文摘 | Wakelee HA Middleton G Dunlop D | 2012 | CancerChemother Pharmacol2012，69，3： | 1 |
| 9 | Role of anti-angiogenesis agents in treating NSCLC: focus on bevaeizumab and VEGFR tyrosine kinase inhibitors显示文摘 | Cabebe E Wakelee H | 2007 | Curr Treat Options Oncol2007，8，1： | 1 |
| 10 | Lung cancer in women:Exploring sex differences in susceptibility,biology,and therapeutic response显示文摘 | Doning Js Le QT Wakelee HA | 2006 | Clin Lung Cancer2006，8，1： | 1 |
| 11 | Cooperative group re- search efforts in lung cancer 2008: focus on advanced-stage non small-cell lung cancer显示文摘 | Wakelee H Kemstine K Vokes E | 2008 | Clin Lung Cancer2008，9，6： | 1 |
| 12 | Treatment,overall survival,and costs in patients with ALK+ non-small cell lung cancer after crizotinib monotherapy显示文摘 | Guerin A Sasane M Wakelee H | 2015 | Curr Med Res Opin2015，31，8： | 1 |
| 13 | Adjuvant chemotherapy for resected non-small cell lung Cancer显示文摘 | Wakelee H Chhatwani L | | 0，，3： | 1 |
| 14 | Sunitinib: a newly approved smallmolecule inhibitor of angiogenesis 显示文摘 | Cabebe E Wakelee H | 2006 | Drugs Today (Barc)2006，42，6： | 1 |
| 15 | Optimizing first-line treatment options for patients with advanced NSCLC显示文摘 | Belanib CP | 2005 | Oncologist2005，10，3： | 1 |
| 16 | Current management of small cell lung cancer显示文摘 | Ne' d JW Gubens MA Wakelee HA | 2011 | Clin Chest Med2011，32，4： | 1 |
| 17 | Targeting VEGF in lung cancer显示文摘 | Millie Das Heather Wakelee | 2012 | Expert Opinion on Therapeutic Targets2012，，： | 1 |
| 18 | Targeting angiogenesis with vascular endothelial growth factor receptor small - molecule inhibitors: novel a-gents with potential in lung cancer 显示文摘 | Wakelee HA Schiller JH | 2005 | Clin Lung Cancer2005，71，： | 1 |
| 19 | Cooperative group research efforts in lung cancer 2008 : focus on Advanced - stage non - small - cell lung cancer显示文摘 | Wakelee H Kemstine K Vokes E | 2008 | Clin Lung Cancer2008，9，6： | 1 |
| 20 | Novel approaches for the treatment of small cell lung cancer显示文摘 | Wakelee H Kelly K | 2004 | Hematol Oncol Clin North Am2004，18，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员